Financing ·
NeOnc Technologies Holdings, Inc. entered into a securities purchase agreement for a registered direct offering of…
NTHINeonc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. entered into a securities purchase agreement for a registered direct offering of common stock and warrants to institutional investors. The company sold 2,610,715 shares of common stock, pre-funded warrants for 960,715 additional shares, and accompanying warrants for 3,571,430 shares at a combined price of $4.20 per share and warrant. Gross proceeds are approximately $15 million before fees. The closing occurred on September 10, 2026. Proceeds will fund working capital and redeem Series A Convertible Preferred Stock. Warrants have a five-year term with a $4.20 exercise price. CEO and CMO executed 90-day lock-up agreements. NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers.